comparemela.com

Latest Breaking News On - மார்கரெட் போடி - Page 1 : comparemela.com

AACR Applauds Appointment of Janet Woodcock, MD, as Acting Commissioner of the FDA

Woodcock’s extraordinary expertise will ensure excellent stewardship in her role as Acting FDA Commissioner PHILADELPHIA The American Association for Cancer Research (AACR), which consists of more than 47,000 laboratory, translational, and clinical researchers; other health care professionals; population scientists; and patient advocates, strongly supports President Biden’s decision to appoint Janet Woodcock, MD, as acting commissioner of the U.S. Food and Drug Administration (FDA). “We look forward to working with Dr. Woodcock and her dedicated colleagues at the FDA to ensure the approval of safe and effective treatments for patients with cancer,” said AACR President Antoni Ribas, MD, PhD, professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program. “Throughout her more than three decades of stellar service at the FDA, Dr. Wood

AACR and MPM award three grants to support groundbreaking cancer research projects

AACR and MPM award three grants to support groundbreaking cancer research projects Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital. The Transformative Cancer Research Grants Program provides generous funds to investigators so they can pursue innovative research which has the potential to help guide and advance cancer treatment and make a significant impact for cancer patients. These grants are part of OIF s impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation. OIF donates a percentage of the fund manager s profits to the impact program, as well as royalties on approved drugs from OIF startup portfolio com

AACR and MPM announce three grants to support transformative cancer research

 E-Mail PHILADELPHIA, PA and CAMBRIDGE, MA - January 19, 2021 Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital. The Transformative Cancer Research Grants Program provides generous funds to investigators so they can pursue innovative research which has the potential to help guide and advance cancer treatment and make a significant impact for cancer patients. These grants are part of OIF s impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation. OIF donates a percentage of the fund manager s profits to the impact program, as well as royalties on approved drugs from OIF startup portfolio companies. To dat

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.